HUS1400011I1 - Új gyógyszer krónikus elzáródásos tüdõbetegség kezelésére - Google Patents

Új gyógyszer krónikus elzáródásos tüdõbetegség kezelésére

Info

Publication number
HUS1400011I1
HUS1400011I1 HUS1400011C HUS1400011C HUS1400011I1 HU S1400011 I1 HUS1400011 I1 HU S1400011I1 HU S1400011 C HUS1400011 C HU S1400011C HU S1400011 C HUS1400011 C HU S1400011C HU S1400011 I1 HUS1400011 I1 HU S1400011I1
Authority
HU
Hungary
Prior art keywords
treatment
chronic obstructive
obstructive pulmonary
pulmonary diseases
novel medicaments
Prior art date
Application number
HUS1400011C
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS1400011(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of HUS1400011I1 publication Critical patent/HUS1400011I1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
HUS1400011C 2002-11-15 2014-03-07 Új gyógyszer krónikus elzáródásos tüdõbetegség kezelésére HUS1400011I1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
EP03778312.3A EP1562603B3 (de) 2002-11-15 2003-11-11 Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung

Publications (1)

Publication Number Publication Date
HUS1400011I1 true HUS1400011I1 (hu) 2022-02-28

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
HUS1400011C HUS1400011I1 (hu) 2002-11-15 2014-03-07 Új gyógyszer krónikus elzáródásos tüdõbetegség kezelésére

Country Status (38)

Country Link
EP (2) EP2025338A1 (hu)
JP (1) JP4317138B2 (hu)
KR (1) KR101092247B1 (hu)
CN (3) CN101817800A (hu)
AR (2) AR041969A1 (hu)
AT (1) ATE430569T1 (hu)
AU (1) AU2003285326B2 (hu)
BE (1) BE2014C016I2 (hu)
BR (1) BRPI0316264B8 (hu)
CA (1) CA2506082C (hu)
CO (1) CO5570670A2 (hu)
CY (2) CY1110500T1 (hu)
DE (2) DE10253282A1 (hu)
DK (1) DK1562603T3 (hu)
EA (1) EA008665B1 (hu)
EC (1) ECSP055774A (hu)
ES (1) ES2326878T7 (hu)
FR (1) FR14C0049I2 (hu)
HR (1) HRP20050432B1 (hu)
HU (1) HUS1400011I1 (hu)
IL (1) IL167900A (hu)
LT (1) LTC1562603I2 (hu)
LU (1) LU92433I2 (hu)
ME (1) ME00354B (hu)
MX (1) MXPA05005081A (hu)
MY (1) MY136034A (hu)
NL (1) NL300650I2 (hu)
NO (2) NO334314B1 (hu)
NZ (1) NZ540661A (hu)
PE (1) PE20040694A1 (hu)
PL (1) PL212238B1 (hu)
PT (1) PT1562603E (hu)
RS (1) RS51607B (hu)
SI (1) SI1562603T1 (hu)
TW (1) TWI343812B (hu)
UA (1) UA81276C2 (hu)
WO (1) WO2004045618A2 (hu)
ZA (1) ZA200502246B (hu)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
PT1781298E (pt) * 2004-04-22 2012-02-03 Boehringer Ingelheim Int Combinações farmacêuticas contendo benzoxazinas para o tratamento de doenças respiratórias
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
JP2007537187A (ja) * 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
US20070088160A1 (en) * 2005-08-15 2007-04-19 Thomas Krueger Process for the manufacturing of betamimetics
TWI396541B (zh) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
TWI389692B (zh) * 2005-10-10 2013-03-21 Boehringer Ingelheim Int 用以吸入β-共效劑的氣溶膠調配物
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
KR20080067699A (ko) * 2005-11-09 2008-07-21 베링거 인겔하임 인터내셔날 게엠베하 흡입용 에어로졸 제형
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007093608A1 (de) * 2006-02-16 2007-08-23 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
SI2013211T1 (sl) 2006-04-21 2012-07-31 Novartis Ag Purinski derivati za uporabo kot agonisti receptorja adenozina A A
US20100222336A1 (en) * 2006-08-07 2010-09-02 Boehringer Ingelheim International Gmbh Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
CN101516885A (zh) 2006-09-29 2009-08-26 诺瓦提斯公司 作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
PT2104535E (pt) 2007-01-10 2011-03-31 Irm Llc Compostos e composições como inibidores da protease de activação de canal
ATE518847T1 (de) * 2007-01-25 2011-08-15 Boehringer Ingelheim Int Verfahren zur herstellung von betamimetika
BRPI0811562A2 (pt) 2007-05-07 2014-12-09 Novartis Ag Compostos orgânicos
ES2602331T3 (es) 2007-12-10 2017-02-20 Novartis Ag Pirazin-carboxamidas de tipo amilorida como bloqueantes de ENaC
EA201001129A1 (ru) 2008-01-11 2011-02-28 Новартис Аг Пиримидины в качестве ингибиторов киназы
ES2535736T3 (es) 2008-06-10 2015-05-14 Novartis Ag Derivados de pirazina como bloqueadores de los canales de sodio epitelial
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
BRPI0923862A2 (pt) 2008-12-30 2015-07-28 Pulmagen Therapeutics Inflammation Ltd Compostos sulfonamida para o tratamento de distúrbios respiratórios
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
AU2010284254B2 (en) 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
US20110098311A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorported Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
JP6084926B2 (ja) * 2010-09-21 2017-02-22 インテクリン・セラピユーテイクス・インコーポレイテツド 抗糖尿病固体医薬組成物
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
CN103492384B (zh) 2011-02-25 2016-05-11 诺华股份有限公司 作为trk抑制剂的化合物和组合物
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
BR112014006223A8 (pt) 2011-09-15 2018-01-09 Novartis Ag 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
JP5886433B2 (ja) 2011-09-16 2016-03-16 ノバルティス アーゲー 嚢胞性線維症処置のためのヘテロ環式化合物
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
JP2015533131A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ２−アドレナリン受容体作動薬
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
EP3134395B1 (en) 2014-04-24 2018-01-31 Novartis AG Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US10112926B2 (en) 2014-04-24 2018-10-30 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
AU2014391608A1 (en) 2014-04-24 2016-10-27 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
US20200069679A1 (en) 2016-12-12 2020-03-05 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
ES2900283T3 (es) 2016-12-20 2022-03-16 Inke Sa Proceso mejorado para la fabricación de clorhidrato de (R)-6-hidroxi-8-[1-hidroxi-2-[2-(4-metoxifenil)-1,1-dimetiletilaminoetil]-2H-1,4-benzoxazin-3(4H)-ona
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
US20200383960A1 (en) 2019-06-10 2020-12-10 Novartis Ag Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
JP2022547427A (ja) 2019-08-28 2022-11-14 ノバルティス アーゲー 置換１，３－フェニルヘテロアリール誘導体及び疾患の治療におけるその使用
WO2021252577A1 (en) * 2020-06-09 2021-12-16 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
CA2405745A1 (en) * 2000-04-27 2001-11-08 Boehringer Ingelheim Pharma Kg New betamimetics having a long-lasting activity, processes for preparingthem and their use as medicaments

Also Published As

Publication number Publication date
ECSP055774A (es) 2005-11-22
NO20052883L (no) 2005-06-14
EP2025338A1 (de) 2009-02-18
WO2004045618A3 (de) 2004-09-30
UA81276C2 (en) 2007-12-25
DE10253282A1 (de) 2004-05-27
ZA200502246B (en) 2006-01-25
DK1562603T3 (da) 2009-09-07
CN101735166A (zh) 2010-06-16
TW200423943A (en) 2004-11-16
KR20050075013A (ko) 2005-07-19
BR0316264A (pt) 2005-10-11
CY2014032I2 (el) 2015-12-09
EA008665B1 (ru) 2007-06-29
NZ540661A (en) 2007-12-21
PL375270A1 (en) 2005-11-28
DE50311502D1 (de) 2009-06-18
EP1562603B1 (de) 2009-05-06
ME00354B (me) 2011-10-10
ES2326878T7 (es) 2014-03-11
CN101817800A (zh) 2010-09-01
HRP20050432B1 (en) 2012-01-31
AU2003285326B2 (en) 2009-06-04
AR087241A2 (es) 2014-03-12
KR101092247B1 (ko) 2011-12-12
ATE430569T1 (de) 2009-05-15
CA2506082C (en) 2011-06-21
EP1562603B3 (de) 2014-01-08
IL167900A (en) 2013-06-27
PT1562603E (pt) 2009-06-18
CY1110500T1 (el) 2015-04-29
CY2014032I1 (el) 2015-12-09
TWI343812B (en) 2011-06-21
JP4317138B2 (ja) 2009-08-19
EP1562603A2 (de) 2005-08-17
BRPI0316264B1 (pt) 2019-04-09
PL212238B1 (pl) 2012-08-31
RS51607B (sr) 2011-08-31
PE20040694A1 (es) 2004-11-23
BRPI0316264B8 (pt) 2021-05-25
JP2006508140A (ja) 2006-03-09
AR041969A1 (es) 2005-06-01
BE2014C016I2 (hu) 2023-03-07
FR14C0049I2 (fr) 2015-07-24
NO2014005I1 (no) 2014-03-10
HRP20050432A2 (en) 2006-06-30
EA200500715A1 (ru) 2005-12-29
LTC1562603I2 (lt) 2016-12-12
CO5570670A2 (es) 2005-10-31
MY136034A (en) 2008-07-31
SI1562603T1 (sl) 2009-10-31
NL300650I2 (nl) 2017-11-02
WO2004045618A2 (de) 2004-06-03
MEP53608A (en) 2011-05-10
CN1713914A (zh) 2005-12-28
LU92433I2 (fr) 2014-06-24
NO334314B1 (no) 2014-02-03
MXPA05005081A (es) 2005-07-01
RS20050361A (en) 2007-04-10
ES2326878T3 (es) 2009-10-21
CA2506082A1 (en) 2004-06-03
FR14C0049I1 (hu) 2014-08-08
AU2003285326A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
HUS1400011I1 (hu) Új gyógyszer krónikus elzáródásos tüdõbetegség kezelésére
AU2003291992A1 (en) Phenylethanolamine derivatives for the treatment of respiratory diseases
HK1081173A1 (en) Phenethanolamine derivative for the treatment of respiratory diseases
AU2003279338A1 (en) Phenethanolamine derivatives for the treatment of respiratory diseases
HK1171736A1 (en) Substituted acids for the treatment of respiratory diseases
IL179906A0 (en) Novel hydantoin derivatives for the treatment of obstructive airway diseases
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
AU2003285091A8 (en) Interferon antagonists useful for the treatment of interferon related diseases
PT1530466E (pt) Utilização de nintedanib para o tratamento de fibrose pulmonar
AU2002338303A1 (en) Therapeutic compositions for the treatment of a respiratory tract disease
HU0102388D0 (en) Diazepinoindoles for the treatment of chronic obstructive pulmonary disease
IL163871A0 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
AU2003294100A8 (en) Use of hyaluronic acid for respiratory disorders or the upper airways
AU2003205898A1 (en) Combination therapy for respiratory disorders
HK1077216A1 (en) Use of thiazole derivatives for the manufacture ofa medicament for the treatment of chronic obstruc tive pulmonary disease
AU2003209542A8 (en) Use of s-substituted l-crysteine for the manufacture of a medicament for the treatment of dermatological disorders
AU4335901A (en) Novel therapeutic treatment of chronic obstructive pulmonary disease
AU2003269257A1 (en) Use of cap-1 for the therapy of asthma
GB0201025D0 (en) The treatment of degenerative diseases
HRP20041159A2 (en) Combination for the treatment of airway disorders
HK1044884A1 (zh) 使用二氮染酮吲(diazepinoindoles)治療慢性阻塞性肺部疾病
AU2003301395A1 (en) Therapeutic agent for chronic obstructive pulmonary disease
GB0211414D0 (en) Treatment of respiratory disorders